2025年2月12日,《自然》杂志发布深度特稿《Dozens of new obesity drugs are coming: these are the ones to watch》,揭示了肥胖症治疗领域的重大突破。礼来制药研发的Bimagrumab作为唯一非GLP-1受体激动剂类药物,在临床研究中展现出革命性效果:通过联合司美格鲁肽治疗,患者Kristian Cook在12个月内实现18kg...
Source Link2025年2月12日,《自然》杂志发布深度特稿《Dozens of new obesity drugs are coming: these are the ones to watch》,揭示了肥胖症治疗领域的重大突破。礼来制药研发的Bimagrumab作为唯一非GLP-1受体激动剂类药物,在临床研究中展现出革命性效果:通过联合司美格鲁肽治疗,患者Kristian Cook在12个月内实现18kg...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.